Target intelligence / Profile preview

DnaJ homolog subfamily C member 2 (DNAJC2)

Target
DNAJC2
Molecular classification
Heat shock protein (Hsp40 family, subfamily C), Molecular chaperone, Chromatin regulator, M-phase phosphoprotein family
01

Overview

DnaJ homolog subfamily C member 2 (DNAJC2) is a multifunctional protein belonging to the heat shock protein 40 (Hsp40) family, specifically the M-phase phosphoprotein (MPP) family, characterized by a J domain and a Myb-type DNA-binding domain[1][3][4]. It functions as both a molecular chaperone—where it forms heterodimers with ribosome-associated complexes to aid the folding and maturation of nascent polypeptides—and a chromatin regulator, with roles in transcriptional activation by binding ubiquitinated histone H2A to displace Polycomb repressive complexes, thus facilitating activation of tumor suppressor genes[1][3][5]. DNAJC2 acts in both the nucleus and cytosol, is essential during embryonic development, and has been linked to several cancers and proliferative disorders, with upregulation in leukemic blasts and colorectal cancer among others[1][3][4][5]. Dysregulation of DNAJC2 has been associated with oncogenic processes, and the gene is considered a potential therapeutic target as well as a biomarker for certain malignancies[1][3].\n\nNo approved drugs or direct small-molecule inhibitors targeting DNAJC2 are documented in open sources[3][4], and established mechanisms of pharmacological modulation have not been described.\n\nIf you need more details (such as specific list of interacting proteins or further disease associations), please specify.

Other names
ZRF1MPP11MPHOSPH11ZUO1Zuotin-related factor 1M-phase phosphoprotein 11DnaJ heat shock protein family member C2
02

Biological functions

Molecular chaperoning (nascent protein folding at ribosome)Chromatin regulation (mediating gene derepression by displacement of Polycomb complexes)RNA bindingHistone bindingTranscriptional regulationProtein foldingRegulation of embryogenesis and stem cell differentiation
03

Disease associations

Cancer (notably leukemia and colorectal cancer)Head and neck squamous cell carcinomaTumorigenesisOther developmental disorders
04

Safety considerations

Potential oncogenic effects due to dysregulation or overexpressionEssential role in development (deletion results in embryonic lethality in animal models)
05

Biomarkers

Upregulated as a leukemia-associated antigen in leukemic blastsOverexpressed in colorectal tumorsPotential candidate biomarker for certain cancers

Beyond the preview

Go deeper on DnaJ homolog subfamily C member 2 (DNAJC2).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on DnaJ homolog subfamily C member 2 (DNAJC2).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call